The European Commission has approved the combination of pembrolizumab, an anti-PD-1 immunotherapy, plus lenvatinib, an oral tyrosine kinase inhibitor, for the first-line treatment of people with advanced renal cell carcinoma (RCC) for use within the European Union (including Northern Ireland). The approval is based on the results from the phase 3 CLEAR/KEYNOTE-581 trial, in which […]
A recent post hoc analysis of the CheckMate 214 trial looked at the nivolumab plus ipilimumab combination in 108 patients with advanced renal cell carcinoma (RCC) who had not had surgery to remove their cancer (nephrectomy). Patients were randomised to nivolumab plus ipilimumab every 3 weeks followed by nivolumab alone (53 patients) or sunitinib every […]
In a recent study, the use of cabozantinib after progression of renal cell carcinoma (RCC) was assessed. Forty-five (45) patients continued with treatment with cabozantinib after their disease had progressed, and 44 patients switched to cabozantinib. Nearly 60% of patients had been treated with two or more prior treatments. Of these patients, most (85%) had […]
The Food and Drug administration (FDA) in the USA has approved pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate or high risk of recurrence following nephrectomy, or for RCC patients after having a nephrectomy and removal of metastases. Adjuvant therapy is medication that is given in addition to surgery to […]
A recent review published in Current Opinion in Supportive and Palliative Care this month has shown that although medicines for the treatment of metastatic renal cell carcinoma (RCC) have improved patient survival, remission and cure of the cancer is rare with medicines alone. In this review, the researchers look at outcomes following nephrectomy and surgical […]
A recent study looked at the efficacy and safety of first-line treatment with a combination of immunotherapies (immune checkpoint inhibitors) for sarcomatoid renal cell carcinoma (RCC). The analysis included five clinical trials involving 568 patients with sarcomatoid RCC. All combinations that were looked at significantly improved progression-free survival and response rate. Combination treatments with nivolumab […]
Treatment of people with intermediate to high risk renal cell carcinoma (RCC) with medicine to prevent the cancer from coming back (adjuvant therapy) can benefit some patients, but it’s important for each patient to weigh the treatment benefit and potential risk of side effects on quality of life. Adjuvant therapy has been shown to delay […]
In a study published in Cancer Cell last week, researchers at the Francis Crick Institute, The Royal Marsden NHS Foundation Trust and UCL have found immune cell patterns within tumours that can help predict if patients with kidney cancer will respond to immunotherapy. The scientists looked at 115 tumour samples from 15 people with metastatic clear […]
The use of radiotherapy for the treatment of metastatic renal cell carcinoma (RCC) is not routine. In a recent study, the use of radiotherapy to delay the use of medicines (systemic therapy) for patients with a small number of RCC metastases (oligometastatic) was assessed. There were 30 patient in the study, al of whom had […]
The first patient has been enrolled in the AURORAX-087A study involving a new liquid biopsy for the detection of recurrence after surgery for clear cell renal cell carcinoma (RCC), the most common form of kidney cancer. The study is taking place at 16 hospitals across Europe and the US, 6 of which are in the […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
